An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
NCT06076291
·
clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
122
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors
Interventions
DRUG:
SG1827
Sponsor
Hangzhou Sumgen Biotech Co., Ltd.